Vitrolife AB (SE:VITR)
:VITR
Want to see SE:VITR full AI Analyst Report?
VITR Stock Chart & Stats
kr133.00
-kr3.40(-1.91%)
At close: 4:00 PM EST
kr133.00
-kr3.40(-1.91%)
Day’s Range― - ―
52-Week Rangekr84.60 - kr160.70
Previous CloseN/A
Volume81.91K
Average Volume (3M)92.36K
Market Cap
kr14.68B
Enterprise Valuekr15.16B
Total Cash (Recent Filing)kr886.00M
Total Debt (Recent Filing)kr1.58B
Price to Earnings (P/E)31.6
Beta0.47
Next Earnings
Jul 16, 2026EPS Estimate
0.95Next Dividend Ex-DateN/A
Dividend Yield0.8%
Share Statistics
EPS (TTM)-37.01
Shares Outstanding135,447,190
10 Day Avg. Volume105,869
30 Day Avg. Volume92,365
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.35
Price to Sales (P/S)5.39
P/FCF Ratio50.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.02
Revenue Forecast (FY)kr3.48B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueVitrolife's core business sells single-use consumables to IVF clinics, producing repeatable revenue tied to treatment volumes. This recurring consumable model creates predictable unit demand, supports revenue resilience over cycles and underpins long-term cash generation independent of episodic equipment sales.
Healthy Gross Margin (~51%)Sustained gross margins near 51% indicate product pricing power and favorable direct-cost structure for core consumables and services. High gross margin provides a structural buffer to absorb SG&A variability and supports potential reinvestment into R&D and market expansion over the medium term.
Strong TTM Cash GenerationPositive and improving TTM operating and free cash flow despite accounting losses shows the business generates real cash from operations. Reliable cash generation enhances financial flexibility for capex, R&D, or M&A, and reduces reliance on external financing during multi-quarter revenue weakness.
Bears Say
Softening Revenue TrendDeclining top-line over recent periods signals structural demand headwinds or loss of share in key markets. For a consumables-driven model, prolonged revenue contraction undermines recurring sales volume, reduces operating leverage and limits the company's ability to stabilize margins and reinvest for longer-term growth.
Volatile, Negative ProfitabilityLarge net losses and swings in operating profit reflect inconsistent cost control or pricing pressures. Persistent negative profitability erodes shareholder equity, constrains dividend and buyback capacity, and may force cost cutting that can harm R&D and sales investments crucial to maintaining competitive position.
Weakened Equity From LossesMaterial reduction in equity due to cumulative losses weakens the balance sheet buffer against future shocks. Even with low leverage, diminished equity limits strategic optionality, raises sensitivity to further losses, and could restrict capital deployment for growth or acquisitions over the medium term.
Vitrolife AB News
VITR FAQ
What was Vitrolife AB’s price range in the past 12 months?
Vitrolife AB lowest stock price was kr84.60 and its highest was kr160.70 in the past 12 months.
What is Vitrolife AB’s market cap?
Vitrolife AB’s market cap is kr14.68B.
When is Vitrolife AB’s upcoming earnings report date?
Vitrolife AB’s upcoming earnings report date is Jul 16, 2026 which is in 54 days.
How were Vitrolife AB’s earnings last quarter?
Vitrolife AB released its earnings results on Apr 23, 2026. The company reported kr0.74 earnings per share for the quarter, missing the consensus estimate of kr0.773 by -kr0.033.
Is Vitrolife AB overvalued?
According to Wall Street analysts Vitrolife AB’s price is currently Overvalued.
Does Vitrolife AB pay dividends?
Vitrolife AB pays a Annually dividend of kr1.1 which represents an annual dividend yield of 0.8%. See more information on Vitrolife AB dividends here
What is Vitrolife AB’s EPS estimate?
Vitrolife AB’s EPS estimate is 0.95.
How many shares outstanding does Vitrolife AB have?
Vitrolife AB has 135,447,190 shares outstanding.
What happened to Vitrolife AB’s price movement after its last earnings report?
Vitrolife AB reported an EPS of kr0.74 in its last earnings report, missing expectations of kr0.773. Following the earnings report the stock price went up 12.265%.
Which hedge fund is a major shareholder of Vitrolife AB?
Currently, no hedge funds are holding shares in SE:VITR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vitrolife AB
Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It provides oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; incubators; cryopreservation; and preimplantation genetic testing products. The company also offers EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; evaluation tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1994 and is headquartered in Gothenburg, Sweden.
Technical Analysis
Getinge
―
BICO Group AB Class B
―
CellaVision AB
―
Xvivo Perfusion AB
―
Sectra AB Class B
―
Options Prices
Currently, No data available
---